- Prof. Joseph Bertino
- Departments of Pharmacology and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Website | E-mail
Special Issue Introduction
Hodgkin and non- Hodgkin lymphoma (HD) and, in particular Diffuse Large Cell Lymphoma, (DLCL) are highly curable in their advanced stages with chemotherapy /immunotherapy .Other types of lymphoma , e.g., mantle cell (MCL)and the low grade lymphoma respond well to systemic treatment but relapse due to drug or immunotherapy resistance. However, there are still as many as 20% of patients with advanced HD, and 30%-40% of patients with DLCL, that relapse, even with some salvage from high dose chemotherapy and stem cell transplantation. Newer treatments, i.e., CAR-T cells and antibody drug conjugates (ADCs) have the potential of increasing cure rates of lymphoma.
There is some understanding of mechanisms contributing to treatment failure of chemotherapy agents, mainly rituximab, methotrexate, oncovin and cyclophosphamide, mainly in experimental tumors, and less understanding in patient tumors. Less is known about resistance to CAR-T and ADCs -both initially and following relapse, and will be key to improving outcome of patients.The value of understanding resistance mechanism is that treatments can be can be found that prevent resistance, or have antitumor activity against acquired resistance in lymphoma as has been shown in the treatment of other tumors, e.g., CML and melanoma. This review is timely and will provide a background and compass for further advances in the treatment of lymphomas.
Submission Deadline30 Apr 2021